Seeing Is Believing
Currently out of the existing stock ratings of Nathan Rich, 25 are a SELL (20.49%), 50 are a BUY (40.98%), 47 are a HOLD (38.52%).
Analyst Nathan Rich, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 73.17% that have a potential upside of 23.64% achieved within 171 days.
Nathan Rich’s has documented 238 price targets and ratings displayed on 22 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on OSCR, Oscar Health at 09-May-2024.
Analyst best performing recommendations are on OSCR (OSCAR HEALTH).
The best stock recommendation documented was for XRAY (DENTSPLY SIRONA) at 12/12/2023. The price target of $32 was fulfilled within 1 day with a profit of $1.01 (3.26%) receiving and performance score of 32.59.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$22
$1.01 (4.81%)
3 years 3 months 26 days ago
(12-Jun-2022)
3/4 (75%)
$1.33 (6.43%)
299
Buy
$21
$0.01 (0.05%)
$26
3 years 4 months 13 days ago
(25-May-2022)
0/4 (0%)
$0.3 (1.45%)
Hold
$21
$0.01 (0.05%)
$19
3 years 4 months 16 days ago
(23-May-2022)
4/5 (80%)
$-1.91 (-8.38%)
397
Hold
3 years 4 months 16 days ago
(22-May-2022)
1/3 (33.33%)
$7.54 (38.75%)
337
Buy
$21
$0.01 (0.05%)
3 years 4 months 16 days ago
(22-May-2022)
1/2 (50%)
$1.3 (6.60%)
54
What Year was the first public recommendation made by Nathan Rich?